Lilly

Weight-Loss Drug Demand Skyrockets: Eli Lilly Boosts Sales Forecast by $2 Billion, Shares Surge 5%

by

INDIANAPOLIS, INDIANA – Eli Lilly’s weight-loss drug Zepbound has seen an explosion in demand, leading the company to increase its annual sales forecast by $2 billion. This surge has also prompted the pharmaceutical company to boost its manufacturing capacity, which in turn has raised its market value above $700 billion, surpassing that of major companies like Tesla and Walmart. The significant increase in production for Zepbound and Lilly’s related diabetes drug Mounjaro is expected in …

Read more

Sleep Apnea Breakthrough: Weight Loss Drug Zepbound Improves Symptoms, Prompts FDA Expansion Review by Eli Lilly

by

Indianapolis, IN – Eli Lilly and Company announced that their weight loss drug Zepbound may have additional benefits for individuals with obstructive sleep apnea. The drugmaker revealed that preliminary trials showed promising results, leading to plans to submit the findings to the US Food and Drug Administration for potential approval to use Zepbound in treating sleep apnea. Obstructive sleep apnea is a common disorder that causes breathing interruptions during sleep, affecting millions of people globally. …

Read more

Weight Loss Drug Zepbound from Eli Lilly Shown to Significantly Reduce Sleep Apnea Events in Adults with Obesity

by

Indianapolis, IN – Eli Lilly’s weight loss drug, Zepbound, has shown promising results in reducing obstructive sleep apnea in adults with obesity, according to a recent announcement by the drugmaker. Obstructive sleep apnea, a condition affecting approximately 39 million adults in the U.S., occurs when a person’s upper airway becomes blocked during sleep, leading to disruptions in airflow throughout the night. The National Heart, Lung, and Blood Institute states that obesity, by narrowing the airway, …

Read more

Weight Loss Drug Zepbound Faces Backorder Issues Across U.S., Eli Lilly & Co. Warns

by

Indianapolis, Indiana – Eli Lilly & Co. announced that availability of their new weight loss drug Zepbound may be impacted as reports of backorders and delays arise throughout the United States. A spokeswoman from Lilly stated that the high demand for these medications may result in challenges for patients attempting to refill their prescriptions at local pharmacies. The company is working to address the issue and alleviate any disruptions in the supply chain. Patients are …

Read more

Weight-Loss Drug Competition Heats Up: Eli Lilly Stock Emerges as IBD Stock Of The Day

by

Indianapolis, Indiana – Eli Lilly stock, with the ticker symbol LLY, has been named Wednesday’s IBD Stock Of The Day as the competition intensifies for Lilly’s weight-loss drug, Zepbound. Shares of Eli Lilly are currently forming a flat base pattern amid these developments. This week, Viking Therapeutics, with the ticker symbol VKTX, announced promising test results for its experimental weight-loss pill, which showed patients losing up to 5.3% of their body weight, outperforming the placebo …

Read more